
|Videos|March 25, 2014
Augmenting the Benefit of Hormonal Therapy in Breast Cancer
Author(s)Debu Tripathy, MD
Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses augmenting the benefit of hormonal therapy in breast cancer.
Advertisement
Clinical Pearls
Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses augmenting the benefit of hormonal therapy in breast cancer.
- The CDK4/6 inhibitor palbociclib has yielded exciting preliminarily results
- In a phase II study, the combination of palbociclib and letrozole tripled PFS compared with letrozole alone (26.1 months versus 7.5 months)
- The HDAC inhibitor entinostat plus hormonal therapy was found to improve survival in a phase II study
- Src inhibition showed benefit in a trial
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































